Acrivon (NASDAQ: ACRV) CLO has 184 shares withheld for RSU tax

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine tax-related share disposition. On May 14, 2026, 184 shares of common stock were withheld at $1.92 per share to cover mandatory tax obligations upon the vesting of restricted stock units. After this withholding, she directly holds 32,937 shares of Acrivon common stock. This was not an open-market sale and reflects standard tax withholding mechanics rather than a discretionary trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miller Mary

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	184	$1.92	$353.28

Holdings After Transaction: Common Stock — 32,937 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Tax-withheld shares: 184 shares Withholding price: $1.92 per share Shares held after transaction: 32,937 shares +1 more

4 metrics

Tax-withheld shares 184 shares Shares delivered to issuer for tax withholding on RSU vesting

Withholding price $1.92 per share Value used for tax-withholding disposition on May 14, 2026

Shares held after transaction 32,937 shares Direct Acrivon common stock holdings after tax withholding

Transaction date May 14, 2026 Date of tax-withholding disposition (Form 4)

Key Terms

restricted stock units, mandatory tax withholding, tax-withholding disposition, Form 4, +1 more

5 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding financial

"to satisfy the mandatory tax withholding requirement"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 04:11 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		F⁽¹⁾		184	D	$1.92	32,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Mary Miller?

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller had 184 common shares withheld to cover taxes upon restricted stock unit vesting. This was a non-market, tax-withholding disposition classified under code F, not an open-market purchase or sale.

Was the ACRV insider transaction by Mary Miller a stock sale on the open market?

No, the transaction was not an open-market sale. The 184 Acrivon shares were withheld by the company to satisfy mandatory tax obligations triggered when restricted stock units vested, a standard compensation-related event rather than a discretionary trade.

How many Acrivon Therapeutics (ACRV) shares were involved in Mary Miller’s Form 4 filing?

The Form 4 shows 184 shares of Acrivon common stock were disposed of through tax withholding at $1.92 per share. These shares were delivered to the issuer to cover taxes connected with the vesting of restricted stock units granted as compensation.

How many ACRV shares does Mary Miller hold after the reported tax withholding?

After the tax-withholding disposition, Mary Miller directly holds 32,937 shares of Acrivon Therapeutics common stock. This post-transaction holding reflects her remaining equity position following the mandatory delivery of 184 shares to satisfy tax requirements on vested restricted stock units.

What does transaction code F mean in the Acrivon Therapeutics (ACRV) Form 4?

Transaction code F signifies payment of an exercise price or tax liability by delivering securities. In this Acrivon filing, 184 shares were withheld by the issuer to meet mandatory tax withholding when restricted stock units vested, rather than being sold on the open market.